NVO Stock Slumps After Late-Stage Trial Fails Primary Goal – Retail Says ‘Current Revenue Drivers’ Still Intact

Novo's Phase 3 trial showed Ziltivekimab did not reduce major adverse cardiovascular events versus placebo.

Novo's stock (NVO) slumped after the trial failed its primary goal.

Retail investors say 'current revenue drivers' remain intact.